NCT06885853Recruiting
Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine
Source: ClinicalTrials.gov · Last updated 15 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study is to evaluate the long-term immunogenicity of a boost dose of MVA-BN vaccine
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 90 (estimated)
- First submitted
- 13 Mar 2025
- Start date
- 7 May 2025
- Primary completion date
- Nov 2026
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- NCT number
- NCT06885853
What you commit to
- Study type: Observational
- Planned participants: 90
- From 7 May 2025 to the primary completion date, Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of mpox (virologically confirmed)
Other
- Be under guardianship or curatorship
- Be subject to a judicial protection measure
- Have a contraindication to vaccination against mpox
Who the study is looking for
- Men aged over 18 years
- Have received two doses of MVA-BN vaccine as an initial schedule
- Eligible for a booster dose of MVA-BN (according to the HAS recommendation)
- Be eligible and wish to initiate PrEP-HIV treatment or be followed for PrEP-HIV treatment
- Covered by social security (excluding AME)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CIC 1417Cochin-Pasteur Coordinator of this site? Confirm its status | Paris | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.